4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Scopolamine.
abobotulinumtoxinA
Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Acepromazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Acepromazine.
Advertisement
Aceprometazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Aceprometazine.
Aclidinium
Scopolamine may increase the anticholinergic activities of Aclidinium.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Scopolamine.
Advertisement
Alfaxalone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Scopolamine is combined with Alfentanil.
Alphaprodine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Alphaprodine.
Advertisement
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Scopolamine.
Ambenonium
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Ambenonium.
Amisulpride
The risk or severity of adverse effects can be increased when Scopolamine is combined with Amisulpride.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Scopolamine.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Scopolamine.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Scopolamine.
Aripiprazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Scopolamine.
Articaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Articaine.
Asenapine
The risk or severity of adverse effects can be increased when Asenapine is combined with Scopolamine.
Atracurium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Atracurium.
Atracurium Besylate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Atracurium besylate.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Scopolamine.
Azelastine
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Scopolamine.
Barbital
The risk or severity of adverse effects can be increased when Scopolamine is combined with Barbital.
Benactyzine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Benactyzine.
Bendroflumethiazide
The serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.
Benoxinate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Benzocaine.
Benzthiazide
The serum concentration of Benzthiazide can be increased when it is combined with Scopolamine.
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Scopolamine.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Benzyl alcohol.
Biperiden
The risk or severity of adverse effects can be increased when Scopolamine is combined with Biperiden.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Scopolamine.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Scopolamine.
Botulinum Toxin Type A
Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Scopolamine.
Brexpiprazole
The risk or severity of adverse effects can be increased when Scopolamine is combined with Brexpiprazole.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Bromazepam
The risk or severity of adverse effects can be increased when Bromazepam is combined with Scopolamine.
Bromperidol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Brompheniramine.
Brotizolam
The risk or severity of adverse effects can be increased when Scopolamine is combined with Brotizolam.
Bupivacaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Bupivacaine.
Buprenorphine
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Scopolamine.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Scopolamine.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Scopolamine.
Butamben
The risk or severity of adverse effects can be increased when Scopolamine is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Scopolamine is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Butorphanol.
Butylscopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Butylscopolamine.
Carbamazepine
The risk or severity of adverse effects can be increased when Carbamazepine is combined with Scopolamine.
Carbinoxamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Carbinoxamine.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Scopolamine.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Chloral hydrate.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Scopolamine.
Chlormethiazole
The risk or severity of adverse effects can be increased when Scopolamine is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Chloroprocaine.
Chlorothiazide
The serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine.
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenoxamine.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Scopolamine.
Chlorprothixene
The risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorprothixene.
Chlorthalidone
The serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Scopolamine.
Citalopram
The risk or severity of adverse effects can be increased when Scopolamine is combined with Citalopram.
Clemastine
The risk or severity of adverse effects can be increased when Clemastine is combined with Scopolamine.
Clidinium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Clidinium.
Clidinium bromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Clidinium.
Clobazam
The risk or severity of adverse effects can be increased when Clobazam is combined with Scopolamine.
Clomipramine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Clomipramine.
Clonazepam
The risk or severity of adverse effects can be increased when Scopolamine is combined with Clonazepam.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Scopolamine.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Scopolamine.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Scopolamine.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Scopolamine.
Cocaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Codeine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Scopolamine is combined with Codeine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Scopolamine is combined with Codeine.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Scopolamine.
Cyclizine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclizine.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.
Cyclopenthiazide
The serum concentration of Cyclopenthiazide can be increased when it is combined with Scopolamine.
Cyclopentolate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopentolate.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Scopolamine.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Scopolamine.
Dantrolene
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.
Dapiprazole
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dapiprazole.
Darifenacin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Darifenacin.
Demecarium
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Demecarium.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Scopolamine.
Desipramine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Desloratadine.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Desvenlafaxine.
Deutetrabenazine
The risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Deutetrabenazine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine.
Dexetimide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dexetimide.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dexmedetomidine.
Dextromoramide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dezocine.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Scopolamine.
Dibucaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Cinchocaine.
Dicyclomine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.
Difenoxin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Difenoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydrocodeine.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dimenhydrinate.
Diphenhydramine
The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Scopolamine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Diphenoxylate.
Dipivefrin
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Dipivefrin.
Distigmine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Distigmine.
Donepezil
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Donepezil.
Doxepin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Doxepin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Scopolamine.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Scopolamine.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Duloxetine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Duloxetine.
Dyclonine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dyclonine.
Echothiophate
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Echothiophate.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Scopolamine.
Edrophonium
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Edrophonium.
Efavirenz
The risk or severity of adverse effects can be increased when Efavirenz is combined with Scopolamine.
Eluxadoline
Scopolamine may increase the constipating activities of Eluxadoline.
Enflurane
The risk or severity of adverse effects can be increased when Scopolamine is combined with Enflurane.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Scopolamine.
Escitalopram
The risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Scopolamine.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Scopolamine.
Ethanol
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ethchlorvynol.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Scopolamine.
Ethotoin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ethotoin.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Etifoxine.
Etomidate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Etomidate.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Scopolamine.
Ezogabine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ezogabine.
Felbamate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Felbamate.
Fentanyl
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fentanyl.
Fesoterodine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.
Fexofenadine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fexofenadine.
Flavoxate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Flavoxate.
Flavoxate Hydrochloride
The risk or severity of adverse effects can be increased when Scopolamine is combined with Flavoxate.
Flibanserin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Flibanserin.
Flunarizine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Flunarizine.
Flunitrazepam
The risk or severity of adverse effects can be increased when Scopolamine is combined with Flunitrazepam.
Fluoxetine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fluoxetine.
Flupenthixol
The risk or severity of adverse effects can be increased when Flupentixol is combined with Scopolamine.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Scopolamine.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Scopolamine.
Fluspirilene
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Scopolamine.
Fluvoxamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fluvoxamine.
Fosphenytoin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Fospropofol.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Scopolamine.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Scopolamine is combined with Gabapentin Enacarbil.
Galantamine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Gallamine Triethiodide.
Ginkgo biloba extract
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Ginkgo biloba.
Glucagon
The risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.
glucagon (rDNA)
The risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.
Glutethimide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Glutethimide.
Glycopyrronium
Scopolamine may increase the anticholinergic activities of Glycopyrronium.
Guanfacine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Guanfacine.
Halazepam
The risk or severity of adverse effects can be increased when Scopolamine is combined with Halazepam.
Haloperidol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Scopolamine.
Halothane
The risk or severity of adverse effects can be increased when Scopolamine is combined with Halothane.
Heroin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Heroin.
Hexobarbital
The risk or severity of adverse effects can be increased when Scopolamine is combined with Hexobarbital.
Homatropine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.
Human Secretin
The therapeutic efficacy of Human secretin can be decreased when used in combination with Scopolamine.
Hydrochlorothiazide
The serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.
Hydrocodone
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroflumethiazide
The serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine.
Hydromorphone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Hydromorphone.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Hyoscyamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Hyoscyamine.
Iloperidone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Iloperidone.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Scopolamine.
incobotulinumtoxinA
Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Indapamide
The serum concentration of Indapamide can be increased when it is combined with Scopolamine.
Ipratropium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.
Ipratropium cation
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Scopolamine.
Isoflurophate
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoflurophate.
Ketamine
The risk or severity of adverse effects can be increased when Ketamine is combined with Scopolamine.
Ketazolam
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ketazolam.
Lamotrigine
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Scopolamine.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Scopolamine.
Levetiracetam
The risk or severity of adverse effects can be increased when Scopolamine is combined with Levetiracetam.
Levobupivacaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Levobupivacaine.
Levocabastine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Levocetirizine.
Levodopa
The risk or severity of adverse effects can be increased when Scopolamine is combined with Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Scopolamine is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Scopolamine is combined with Levomilnacipran.
Levorphanol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Levorphanol.
Lidocaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Lidocaine.
Lithium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Lithium.
Lithium Cation
The risk or severity of adverse effects can be increased when Scopolamine is combined with Lithium.
Lofexidine
The therapeutic efficacy of Scopolamine can be increased when used in combination with Lofexidine.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Scopolamine.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Scopolamine.
Lormetazepam
The risk or severity of adverse effects can be increased when Scopolamine is combined with Lormetazepam.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Scopolamine.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine.
Magnesium Sulfate
The therapeutic efficacy of Scopolamine can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Scopolamine can be increased when used in combination with Magnesium sulfate.
Malathion
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Malathion.
Maprotiline
The risk or severity of adverse effects can be increased when Scopolamine is combined with Maprotiline.
Mecamylamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Mecamylamine.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Scopolamine.
Mefloquine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Mefloquine.
Melatonin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Melatonin.
Memantine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Memantine.
Meperidine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pethidine.
Mephobarbital
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methylphenobarbital.
Mepivacaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine.
Mesoridazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Mesoridazine.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Scopolamine.
Methadone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methadyl Acetate.
Methantheline
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methantheline.
Methapyrilene
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methaqualone.
Methixene
The risk or severity of adverse effects can be increased when Scopolamine is combined with Metixene.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Scopolamine.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Scopolamine.
Methotrimeprazine
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methoxyflurane.
Methscopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methscopolamine.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methylscopolamine bromide.
Methsuximide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Methsuximide.
Methyclothiazide
The serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.
Metoclopramide
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Metoclopramide.
Metolazone
The serum concentration of Metolazone can be increased when it is combined with Scopolamine.
Metylperon
The risk or severity of adverse effects can be increased when Scopolamine is combined with Melperone.
Metyrosine
Scopolamine may increase the sedative activities of Metyrosine.
Mianserin
Mianserin may increase the anticholinergic activities of Scopolamine.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Scopolamine.
Milnacipran
The risk or severity of adverse effects can be increased when Scopolamine is combined with Milnacipran.
Minaprine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Minaprine.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Mirabegron
The risk or severity of adverse effects can be increased when Scopolamine is combined with Mirabegron.
Mirtazapine
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Molindone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Molindone.
Morphine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Morphine.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Nalbuphine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Nalbuphine.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Scopolamine.
Nefazodone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone.
Neostigmine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Neostigmine.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Scopolamine.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Scopolamine.
Nordazepam
The risk or severity of adverse effects can be increased when Scopolamine is combined with Nordazepam.
Norflurane
The risk or severity of adverse effects can be increased when Scopolamine is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Normethadone.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Scopolamine.
O-PHENANTHROLINE
The therapeutic efficacy of Scopolamine can be decreased when used in combination with 1,10-Phenanthroline.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Anisotropine Methylbromide.
Octylonium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Otilonium.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Scopolamine.
Olopatadine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Olopatadine.
onabotulinumtoxinA
Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Ondansetron
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ondansetron.
Opium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Opium.
Orphenadrine
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Scopolamine.
Oxitropium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxitropium.
Oxprenolol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxprenolol.
Oxybutynin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybutynin.
Oxycodone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxymorphone.
Oxyphenonium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxyphenonium.
Paliperidone
The risk or severity of adverse effects can be increased when Paliperidone is combined with Scopolamine.
Pancuronium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.
Pancuronium Bromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.
Paraldehyde
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The risk or severity of adverse effects can be increased when Scopolamine is combined with Morphine.
Paroxetine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Scopolamine.
Pentazocine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pentazocine.
Pentobarbital
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Scopolamine.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Perazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Perazine.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Scopolamine.
Phenobarbital
The risk or severity of adverse effects can be increased when Phenobarbital is combined with Scopolamine.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Phenoxyethanol.
Phenytoin
The risk or severity of adverse effects can be increased when Phenytoin is combined with Scopolamine.
Physostigmine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Physostigmine.
Pimozide
The risk or severity of adverse effects can be increased when Pimozide is combined with Scopolamine.
Pipamperone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pipamperone.
Pipecuronium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pipecuronium.
Pipothiazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pipotiazine.
Pirenzepine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pirenzepine.
Pirinitramide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Piritramide.
Pizotyline
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pizotifen.
Polythiazide
The serum concentration of Polythiazide can be increased when it is combined with Scopolamine.
Pomalidomide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pomalidomide.
Potassium Chloride
Scopolamine may increase the ulcerogenic activities of Potassium Chloride.
Pramipexole
Scopolamine may increase the sedative activities of Pramipexole.
Pramlintide
Pramlintide may increase the anticholinergic activities of Scopolamine.
Pramoxine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pramocaine.
Prazepam
The risk or severity of adverse effects can be increased when Scopolamine is combined with Prazepam.
Pregabalin
The therapeutic efficacy of Scopolamine can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Prilocaine.
Primidone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Primidone.
Procaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Procaine.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.
Procyclidine
The risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine.
Profenamine
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Scopolamine.
Promazine
The risk or severity of adverse effects can be increased when Promazine is combined with Scopolamine.
Promethazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Promethazine.
Propantheline
The risk or severity of adverse effects can be increased when Scopolamine is combined with Propantheline.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Propantheline.
Proparacaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Proparacaine.
Propiverine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Propiverine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Scopolamine.
Propoxyphene
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dextropropoxyphene.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine.
Pyridostigmine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pyridostigmine.
Pyridostigmine Bromide
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pyridostigmine.
Quazepam
The risk or severity of adverse effects can be increased when Quazepam is combined with Scopolamine.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Scopolamine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Quetiapine is combined with Scopolamine.
Quinethazone
The serum concentration of Quinethazone can be increased when it is combined with Scopolamine.
Quinidine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Quinidine.
Ramelteon
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ramelteon.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Scopolamine.
Remifentanil
The risk or severity of adverse effects can be increased when Scopolamine is combined with Remifentanil.
Remoxipride
The risk or severity of adverse effects can be increased when Scopolamine is combined with Remoxipride.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Scopolamine.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Scopolamine.
rimabotulinumtoxinB
Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type B.
Risperidone
The risk or severity of adverse effects can be increased when Risperidone is combined with Scopolamine.
Rivastigmine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Rivastigmine.
Ropinirole
Scopolamine may increase the sedative activities of Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ropivacaine.
Rotigotine
Scopolamine may increase the sedative activities of Rotigotine.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Scopolamine.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Scopolamine.
Secretin
The therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine.
Sertindole
The risk or severity of adverse effects can be increased when Scopolamine is combined with Sertindole.
Sertraline
The risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Scopolamine.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Scopolamine.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Solifenacin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Solifenacin.
Sufentanil
The risk or severity of adverse effects can be increased when Scopolamine is combined with Sufentanil.
Sulpiride
Scopolamine may increase the anticholinergic activities of Sulpiride.
Suvorexant
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tacrine
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Tacrine.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Tasimelteon
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tasimelteon.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Scopolamine.
Tetrabenazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrabenazine.
Tetracaine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Thalidomide
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Thiamylal
The risk or severity of adverse effects can be increased when Scopolamine is combined with Thiamylal.
Thiopental
The risk or severity of adverse effects can be increased when Scopolamine is combined with Thiopental.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Thiopental.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Scopolamine.
Thiothixene
The risk or severity of adverse effects can be increased when Thiothixene is combined with Scopolamine.
Tiagabine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tiagabine.
Tiapride
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tiapride.
Tiotropium
Scopolamine may increase the anticholinergic activities of Tiotropium.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Scopolamine.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Scopolamine.
Tolterodine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tolterodine.
Topiramate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Topiramate.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Scopolamine.
Tramadol
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tramadol.
Tranylcypromine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tranylcypromine.
Trazodone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Trazodone.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Scopolamine.
Triazulenone
The risk or severity of adverse effects can be increased when Scopolamine is combined with Loprazolam.
Trichlormethiazide
The serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.
Trifluoperazine
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Scopolamine.
Triflupromazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Triflupromazine.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine.
Trimethaphan
The risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethaphan.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Scopolamine.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Scopolamine.
Tropicamide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tropicamide.
Trospium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Trospium.
Tubocurarine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Tubocurarine.
Tyrothricin
The therapeutic efficacy of Scopolamine can be decreased when used in combination with Tyrothricin.
Umeclidinium
Scopolamine may increase the anticholinergic activities of Umeclidinium.
Urethane
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl carbamate.
Valproate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Valproic Acid.
Valproic Acid
The risk or severity of adverse effects can be increased when Scopolamine is combined with Valproic Acid.
Vecuronium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.
Venlafaxine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine.
Vigabatrin
The risk or severity of adverse effects can be increased when Scopolamine is combined with Vigabatrin.
Vincristine
The excretion of Vincristine can be decreased when combined with Scopolamine.
Vortioxetine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Vortioxetine.
Xylazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Xylazine.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Scopolamine.
Ziconotide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ziconotide.
Ziprasidone
The risk or severity of adverse effects can be increased when Ziprasidone is combined with Scopolamine.
Zolpidem
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Zonisamide.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Scopolamine.
Zotepine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Zotepine.
Zuclopenthixol
The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Scopolamine.
